Clare joined EnPlusOne in 2025 as CEO, bringing significant experience as a company builder, deal maker, and drug developer in the biotechnology industry.
Clare was previously a co-founder of Life Edit Therapeutics, a subsidiary of ElevateBio, where she was a member of the executive leadership team and most recently served as Senior Vice President for Corporate Development and Operations. At Life Edit, Clare led the company through several important milestones including developing and closing transformational deals with Moderna and Novo Nordisk, and advancing programs from indication selection through development candidate nomination. Prior to joining Life Edit, Clare worked at Evotec, SCYNEXIS and Novartis.
Clare Holds an MBA from The Fuqua School of Business, Duke University, a PhD in synthetic organic chemistry from the University of Liverpool, and a BSc in Chemistry from the University of Liverpool.
Jonathan is Co-founder and CSO of EnPlusOne Bio. He performed his graduate work in organic synthesis at Indiana University in Bloomington, Indiana. During his time there, he secured a Briscoe Fellowship and worked in the laboratory of Professor Michael Vannieuwenhze. Much of this work was toward synthesizing 1) novel fluorescent probes to spy on bacteria and 2) macrocyclic natural products to kill them. He joined George Church’s Research Group at Harvard Medical School where he helped develop an enzymatic RNA synthesis platform that formed the technical basis of EnPlusOne Bio. Jonathan earned his BS in Chemistry from Indiana Wesleyan University and a PhD in Organic Chemistry from Indiana University.
Dan is Co-founder, COO, and Board Director of EnPlusOne Bio. He joined the team while attending business school and was introduced to the scientific co-founders through participation in the Nucleate Program at Harvard. During this experience, Dan became convinced EnPlusOne had the technology and team to tackle the many problems facing RNA synthesis. Upon graduation, Dan was selected as a Blavatnik Fellow in Life Science Entrepreneurship which provided resources and mentorship instrumental in founding EnPlusOne. Working in the cutting-edge space of RNA is well-aligned with his passion for the biotechnology industry and rare diseases. Previously, he worked at Sanofi as a process engineer supporting large scale cGMP manufacturing of enzyme replacement therapies. Most recently, he led the design, construction, and validation of purification operations for a new continuous biomanufacturing facility, awarded the 2020 ISPE Facility of the Year. Dan earned his BS in Chemical Engineering from Northeastern University and an MBA from Harvard Business School.
Bob is the Director of Engineering at EnPlusOne Bio. He has over 25 years of experience in the Biotechnology industry with process equipment and system design. Prior to joining EnPlusOne, he was the Process Design Lead at Sanofi for their multi-product cGMP manufacturing facility (2020 ISPE Facility of the Year). Over a four-year period, he led a group of engineers who were responsible for the design, fabrication oversight, start-up and commissioning of the process unit operations for two full-scale manufacturing suites. Bob’s thorough understanding of bioprocess unit operations and the design requirements necessary to support compliant GMP operation will be valuable as EPO scales the process. Bob earned his BS in Mechanical Engineering from the University of Massachusetts.
Ella is the Lead of RNA Synthesis focused on driving development of the company’s ezRNATM platform. Ella previously worked at Northpond Ventures and the Wyss Institute, where she met the EnPlusOne team. For her undergrad she completed a thesis on small molecule binding sites in intrinsically disordered proteins. Ella holds a Bachelor of Science in Biochemistry from Georgetown University and a Masters in Chemistry from Yale.
Dominic is a Scientist at EnPlusOne, specializing in organic synthesis. He is a recent graduate from Massachusetts College of Pharmacy and Health Sciences, where he received a Bachelor of Science in Chemistry and a Master of Science in Pharmaceutical Chemistry. While attending university, Dominic worked as a Research Intern for the Lencer and Loddenkemper laboratories at Harvard Medical School and Boston Children’s Hospital. His undergraduate research was focused on the synthesis of ultra-pure fluorescent probes for inclusion in plastic scintillators. His Master’s Thesis concerned the synthesis of a dopamine agonist as a drug target for cocaine abuse disorder.
